CBIO
Crescent Biopharma, Inc. Health Care Pharmaceutical Preparations Russell 3000
$13.48Close
$371.5MMarket cap
$8.94 – $26.9852-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 45 · weaker than 55% of stocks over 12 months
- Far from its high 50% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
50%
1wk
up 5.1%
price change
1mo
down 7.6%
price change
12-month return
up 8%
market up 11% ·
its own down 3%
F-score
—
— Not assessed
Altman Z
3.93
Low risk
P/E
2413.0×
price / earnings
PEG
—
P/E / EPS growth
P/B
1.8×
price / book
Earnings yield
down 96.4%
EBIT / enterprise value
Cheaper than
26%
of the market · expensive
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
0%
return on equity
Free cash margin
down 668%
-$72.5M FCF
D/E
0.00
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Long-term debt down 100% ($0.0B → $0.0B)
Trade setup
ATR%
8.1%
$1.10 a day · 2×ATR $11.29
RS
45 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
0.5×
vs 50-day average
Up/down volume
1.13
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 2605.3% over the year, from 1m to 28m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Profit not backed by cash Reported profit of $153,942 came with -$71.5M of operating cash flow. Profit that cash does not follow is the classic signature of aggressive accounting.
Last reported
Jul 30, 2026
Financials
- Net 1%
- Free cash -668%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $10.2M | $1.2M | $75,000 | $10,000 | — | $10.8M |
| Operating income | -$51.5M | -$63.4M | -$47.4M | -$39.3M | -$40.0M | -$152.6M |
| Net income | -$51.0M | -$63.4M | -$46.7M | $36,899 | $37,879 | $153,942 |
| Net margin | -502% | -5469% | -62252% | 369% | — | 1% |
| Earnings per share | -$1.12 | -$1.23 | -$0.89 | $0.00 | $0.00 | — |
| Free cash flow | -$39.3M | -$57.5M | -$46.5M | -$34.9M | -$31.1M | -$72.5M |
| Free cash margin | -387% | -4958% | -62056% | -349013% | — | -668% |
| Cash | $137.0M | $90.3M | $47.9M | $41.8M | $34.8M | $213.2M |
| Long-term debt | — | — | — | — | $37.5M | $0 |
| Shareholders' equity | $128.2M | $81.6M | $42.9M | $38.4M | -$15.5M | $203.0M |
| Shares outstanding | 49.02m | 52.31m | 54.38m | 64.39m | 1.02m | 27.56m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| Apr 29, 2026 | Quarterly ↗ | Mar 31, 2026 | 29d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Jul 31, 2025 | Quarterly ↗ | Jun 30, 2025 | 31d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Feb 13, 2025 | Annual ↗ | Dec 31, 2024 | 44d |
| Nov 13, 2024 | Quarterly ↗ | Sep 30, 2024 | 44d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 27, 2024 | Annual ↗ | Dec 31, 2023 | 87d |
| Nov 3, 2023 | Quarterly ↗ | Sep 30, 2023 | 34d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 15, 2026 | Other events ↗ |
| Jul 30, 2026 | Results ↗ |
| Jul 15, 2026 | Other events ↗ |
| Jul 14, 2026 | Results ↗ |
| Jun 3, 2026 | Shareholder vote ↗ |
| Apr 29, 2026 | Results ↗ |
| Feb 26, 2026 | Results ↗ |
| Dec 4, 2025 | Material agreement · Unregistered share sale · Regulation FD · Other events ↗ |
| Nov 6, 2025 | Results ↗ |
| Jul 31, 2025 | Results · Director or officer change ↗ |
| Jun 18, 2025 | Material agreement · Acquisition or disposal · Results · Holder rights changed · Auditor change · Change of control · Director or officer change · Charter or bylaws · Item 5.05 · Item 5.06 · Regulation FD ↗ |
| Jun 6, 2025 | Shareholder vote · Regulation FD · Other events ↗ |